Dried blood spot assay for the quantification of phenytoin using Liquid Chromatography-Mass Spectrometry

Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti‐epileptic drugs

“…On the basis of this result, Kong et al developed the following estimation equation: C p = (1.11 × C dbs /[1‐(0.71 × Hct)]) ‐ 1.00 μg/mL. Villanelli et al reported that C dbs was highly correlated with C p after adjusting for Hct levels, which is consistent with findings of other studies ( r 2 = 0.982). However, C p and C dbs were log‐transformed when compared.…”

Neonatal medicines research: challenges and opportunities

“…The development of such methods to measure a range of environmental toxicants, excipients or drugs in DBS has been a more recent goal. The approach has been proved to be effective in the field of neonatal pharmacology, based on compoundspecific reports, for example, caffeine, diphantoine or fenytoine, topiramate, canrenoate, propranolol, linezolid, metronidazole or dexamethasone [39][40][41][42][43][44]49,51].…”

“…The technique itself has been introduced already a long time ago in neonatal care to screen for phenylketonuria, and became well established for applications such as the broader neonatal screening for inborn (metabolic) diseases. The same methodological approach has more recently experienced a novel surge of interest in the context of drug development, that is, toxicokinetic and PK studies, and of clinical pharmacotherapy, that is, therapeutic drug monitoring (TDM) [35,[41][42][43][44][45][46][47][48][49][50].…”

A methodological approach to the selection of liquid reagents for chemical ionization ion trap-gas chromatography mass spectrometry: A case study of GBL and 1,4-BD

“…Hence for evaluation of the actual LOD values, the use of the SE-y and limit the range of the regression curve (25-250 and 100-1000 ng/mL for GBL and 1,4-BD respectively) it is considered more appropriate [21].…”